Clovis Oncology announced today the pricing of an underwritten public offering of 3333334 shares of its common stock at $72.00 per share before underwriting discounts and commissions.
The size of the offering was upsized from $170 million to $240 million. In addition the underwriters have a 30-day option to purchase up to an additional 486110 shares of common stock from Clovis Oncology to cover over-allotments if any.
The offering is expected to close on June 17 2013 subject to customary closing conditions.
Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes including funding of its development programs general and administrative expenses acquisition or licensing of additional product candidates or businesses and working capital.
J. P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering and Leerink Swann LLC is acting as co-manager for the offering.
The shares of Clovis Oncology common stock described above are being offered only by means of prospectuses and prospectus supplements pursuant to two effective shelf registration statements previously filed with the Securities and Exchange Commission.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Clovis Oncology
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring developing and commercializing innovative anti-cancer agents in the U.S. Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder Colorado and has additional offices in San Francisco California and Cambridge UK.